# DEA Rescheduled Marijuana: Key Regulatory Update March 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-rescheduled-marijuana-regulatory-update-march-2026/ > **Published:** 2026-03-20T00:27:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:04:43-04:00 > **Clinical Summary:** Explore the DEA rescheduled marijuana update and its impact on medical cannabis practice in March 2026 regulatory news. --- Policy WatchMarch 20, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011) This regulation schedules three synthetic opioids as controlled substances, with minimal direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) unless cannabis is considered as an alternative [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) option in clinical practice. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013) This regulatory item addresses Schedule I placement of ethylphenidate, a controlled substance unrelated to cannabis, and has no direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001) This regulation temporarily schedules two synthetic opioids in Schedule I but does not directly impact cannabis clinical practice, as it addresses different controlled substances outside the [cannabis regulatory framework](https://cedclinic.com/medical-cannabis-framework-philippines-legislative-advances/). [Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001) Score 70Regulations.gov [Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001) Regulatory Summary DEA authorization for controlled-biopharmaceutical importation (2024-20085) establishes licensing requirements enabling qualified entities to import cannabis-derived pharmaceutical products for clinical use and [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/). [Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001) Score 70Regulations.gov [Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003) This DEA action schedules synthetic opioids, not cannabis, but affects [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) alternatives available to patients currently using cannabis therapeutics for pain relief. [Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003) Score 70Regulations.gov [Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001) Regulatory Summary The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing medical utility and reducing prescribing restrictions for qualified healthcare providers treating patients. [Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001) Score 70Regulations.gov [Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052) This firearms regulation defines dealer licensing requirements and has no direct relevance to cannabis clinicians or patients, as it addresses federal weapons commerce rather than cannabis medical practice or treatment. [Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006) The DEA placed three synthetic opioids in Schedule I, establishing stricter controls on substances with abuse potential—relevant to cannabis clinicians managing pain patients who may encounter these controlled alternatives. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007) This regulatory action schedules three synthetic opioids in Schedule I; it is not directly relevant to cannabis clinicians or patients as it addresses different controlled substances. [Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007) Score 70Regulations.gov [Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001) Regulatory Summary The DEA placed 2-Methyl AP-237, a synthetic opioid, into Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis clinicians treating patients who may use multiple controlled substances. [Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Policy Watch: 20 Regulatory Updates — March 20, 2026](https://cedclinic.com/drug-enforcement-controlled-substances-regulatory-policy-2026/) A comprehensive overview of 20 regulatory updates including cannabis and controlled substances on March 20, 2026. [Read More](https://cedclinic.com/drug-enforcement-controlled-substances-regulatory-policy-2026/) [Policy Watch: 10 Regulatory Updates — March 18, 2026](https://cedclinic.com/dea-marijuana-rescheduling-2026-regulatory-updates/) Review the latest 10 regulatory updates relevant to cannabis medicine from March 18, 2026. [Explore Updates](https://cedclinic.com/dea-marijuana-rescheduling-2026-regulatory-updates/) [Policy Watch: 27 Regulatory Updates — March 16, 2026](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) Detailed insights on 27 regulatory changes affecting cannabis and controlled substances as of March 16, 2026. [Learn More](https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Policy%20Watch%3A%2010%20Regulatory%20Updates%20%E2%80%94%20March%2020%2C%202026&url=https%3A%2F%2Fcedclinic.com%2Fdea-rescheduled-marijuana-regulatory-update-march-2026%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdea-rescheduled-marijuana-regulatory-update-march-2026%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Policy%20Watch%3A%2010%20Regulatory%20Updates%20%E2%80%94%20March%2020%2C%202026%20https%3A%2F%2Fcedclinic.com%2Fdea-rescheduled-marijuana-regulatory-update-march-2026%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).